Cor Vasa 2024, 66(2):99-102 | DOI: 10.33678/cor.2024.022

(Fixed combination and adherence in patients with recent myocardial infarction or manifest cardiovascular disease - our experience from the SECURE trial)

Jean-Claude Lubandaa, b, Hana Lubandab
a II. interní klinika kardiologie a angiologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha, Česká republika
b Centrum kardiovaskulární medicíny s.r.o, Praha, Česká republika

A lack of adherence is associated with a worse prognosis. Decreasing adherence in post-MI patients leads to an increased risk of recurrence of ischemic events. In addition, due to the aging population and improved quality care for ACS with better survival, there is an increase in the number of patients who need more personalized secondary preventive interventions. For these patients, improving adherence is another way to improve their prognosis. The latest research shows that combination therapy, preferably in a fixed combination, should improve patient adherence and reduce the risk of CV disease complications. Thanks to the reduction in the number of tablets, the patient can stay on therapy for a longer period, because it is easier than using several tablets at once. The use of fixed combinations therapy in patients after MI as soon as possible, ideally already at discharge, leads to a significant improvement in adherence and a reduction in the risk of recurrence of ischemic events and a reduction in cardiovascular death, as demonstrated by the SECURE study. We should be able to ensure maximum patient adherence to treatment by administering fixed combinations of drugs with a proven efficacy especially an improvement of cardiovascular outcome.

Keywords: Acute coronary syndrome, Adherence, Arterial hypertension, Cardiovascular mortality, Fixed combination, Myocardial infarction, Polypill, Secondary prevention, SECURE study

Received: February 5, 2024; Revised: February 5, 2024; Accepted: March 9, 2024; Prepublished online: June 2, 2012; Published: April 26, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lubanda J, Lubanda H. (Fixed combination and adherence in patients with recent myocardial infarction or manifest cardiovascular disease - our experience from the SECURE trial). Cor Vasa. 2024;66(2):99-102. doi: 10.33678/cor.2024.022.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1151-1210. Go to original source... Go to PubMed...
    2. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1736-1788. Go to original source... Go to PubMed...
    3. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289-1367. Go to original source... Go to PubMed...
    4. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013;34:2940-2948. Go to original source... Go to PubMed...
    5. Castellano JM, Sanz G, Penalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol 2014;64:2071-2082. Go to original source... Go to PubMed...
    6. Bansilal S, Castellano JM, Garrido E, et al. Assessing the impact of medication adherence on long-term cardiovascular outcomes. J Am Coll Cardiol 2016;68:789-801. Go to original source... Go to PubMed...
    7. Smaje A, Weston-Clark M, Raj R, et al. Factors associated with medication adherence in older patients: a systematic review. Aging Med (Milton) 2018;1:254-266. Go to original source... Go to PubMed...
    8. Caldeira D, Vaz-Carneiro A, Costa J. The impact of dosing frequency on medication adherence in chronic cardiovascular disease : systematic review and metaanalysis. Rev Port Cardiol 2014;33:431-437. Go to original source... Go to PubMed...
    9. Kotseva K, EUROASPIRE Investigators. The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention. Cardiovasc Diagn Ther 2017;7:633-639. Go to original source... Go to PubMed...
    10. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227-3337. Go to original source... Go to PubMed...
    11. Hradec J. Adherence v České republice. Med promoci 2019;20:1-7.
    12. Akincigil A, Bowblis JR, Levin C, et al. Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction. J Gen Intern Med 2008;23:115-121. Go to original source... Go to PubMed...
    13. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006;166:1842-1847. Go to original source... Go to PubMed...
    14. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155:772-779. Go to original source... Go to PubMed...
    15. Castellano JM, Sanz G, Fernandez Ortiz A, et al. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. J Am Coll Cardiol 2014;64:613-621. Erratum in: J Am Coll Cardiol 2014;64:1539. Go to original source... Go to PubMed...
    16. Choudhry NK, Glynn RJ, Avorn J, et al. Untangling the relationship between medication adherence and post- -myocardial infarction outcomes: medication adherence and clinical outcomes. Am Heart J 2014;167:51.e5-58.e5. Go to original source... Go to PubMed...
    17. Desta L, Khedri M, Jernberg T, et al. Adherence to beta- -blockers and long-term risk of heart failure and mortality after a myocardial infarction. ESC Heart Fail 2021;8:344-355. Go to original source... Go to PubMed...
    18. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed- -dose combinations improve medication compliance: a meta- -analysis. Am J Med 2007;120:713-719. Go to original source... Go to PubMed...
    19. Simons LA, Chung E, Ortiz M. Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Curr Med Res Opin 2017;33:1783-1787. Go to original source... Go to PubMed...
    20. Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med 2022;387:967-977. Go to original source... Go to PubMed...
    21. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023;41:1874-2071. Go to original source... Go to PubMed...
    22. Masi S, Kobalava Z, Veronesi C, et al. Real-world analysis on drug utilization, cardiovascular hospitalization and healthcare costs of patients on single pill vs free combination of perindopril/bisoprolol in Italy. J Hypertens 2023;41(Suppl 3):e81. Go to original source...
    23. Byrne RA, Rossello X, Coughlan JJ, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:3720-3826. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes